Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy

• Status: Unknown status
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Akershus
• Collaborators: AstraZeneca; Oslo University Hospital
• Treatments: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Persisting self-reported depressive symptoms > 5 weeks

• Indications of aortic atherosclerosis on PET/CT

Exclusion Criteria:

• Clinical indication of statin use.

• Contraindication of statins, or of PET/CT and MRI.

• Established cardiovascular disease.

• Bipolar disorder og comorbid psychosis.